Sitzia J, North C, Stanley J, Winterberg N
Worthing Nursing Development Unit, Worthing Hospital, United Kingdom.
Cancer Nurs. 1997 Dec;20(6):430-9. doi: 10.1097/00002820-199712000-00007.
Cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisolone (CHOP) has for many years been the standard chemotherapeutic regimen for patients with aggressive non-Hodgkin's lymphoma. Published data for side effects experienced by patients undergoing CHOP chemotherapy in the treatment of non-Hodgkin's lymphoma are limited and inconsistent. No broad descriptive work appears to have been carried out. This study aimed to describe the range of problems experienced by patients receiving CHOP and to estimate incidence and severity of side effects over the treatment period. Data were collected at each treatment cycle via a 75-item self-report questionnaire, with severity of each side effect graded on a 5-point scale. The instrument has previously been shown to be reliable and valid. Nineteen participants received 99 cycles of CHOP and returned 74 questionnaires (response rate = 75%). Patients reported a total of 80 side effects. Alopecia was the most common problem, with all patients experiencing some hair loss by cycle 3. Fatigue was the second most common side effect (incidence = 77%) and taste change the third (incidence = 74%). Patients judged postchemotherapy nausea to be the "most troublesome" problem, followed by fatigue, taste change, constipation, and difficulty sleeping. Both nausea and fatigue were most problematic in the first part of the treatment course. These results indicate that patients receiving CHOP experience a wide range of problems, many of which merit further investigation.
环磷酰胺、阿霉素、长春新碱（Oncovin）和泼尼松龙（CHOP）多年来一直是侵袭性非霍奇金淋巴瘤患者的标准化化疗方案。关于接受CHOP化疗治疗非霍奇金淋巴瘤的患者所经历副作用的已发表数据有限且不一致。似乎尚未开展广泛的描述性研究。本研究旨在描述接受CHOP治疗的患者所经历的问题范围，并估计治疗期间副作用的发生率和严重程度。在每个治疗周期通过一份包含75个项目的自我报告问卷收集数据，每个副作用的严重程度按5分制分级。该工具此前已被证明可靠且有效。19名参与者接受了99个周期的CHOP治疗，并返回了74份问卷（回复率 = 75%）。患者共报告了80种副作用。脱发是最常见的问题，到第3个周期时所有患者都出现了一定程度的脱发。疲劳是第二常见的副作用（发生率 = 77%），味觉改变是第三常见的副作用（发生率 = 74%）。患者认为化疗后恶心是“最麻烦”的问题，其次是疲劳、味觉改变、便秘和睡眠困难。恶心和疲劳在治疗过程的第一阶段问题最为严重。这些结果表明，接受CHOP治疗的患者会经历广泛的问题，其中许多问题值得进一步研究。
